Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...

Another company that was once ahead in the RCC drug race was Merck MRK, whose chronic cough drug, gefapixant, received two ...

It's worth noting that the agreement has been forged a few months after Merck suffered a setback in its attempt to secure FDA approval for a potentially first-in-class drug for chronic cough ...

Trevi is also conducting the phase IIb CORAL study, which is evaluating the drug in idiopathic pulmonary fibrosis (IPF) patients with chronic cough. Data from this study is expected in the first ...